Вплив високоактивної антиретровірусної терапії на функціональний стан серцево-судинної системи (огляд літератури)
DOI:
https://doi.org/10.24061/2413-0737.XIX.1.73.2015.51Ключові слова:
ВІЛ-інфекція/СНІД, серцево-судинна система, антиретровірусна терапіяАнотація
Наведені сучасні дані щодо ризику серцево-судинних захворювань серед ВІЛ-інфікованих хворих, які перебувають на безперервній та інтермітуючій високоактивній антиретровірусній терапії. Особлива увага приділена питанню вивчення патофізіологічних механізмів розвитку таких ускладнень.
Посилання
D'yachenko AG, D'yachenko PA, Gorobchenko EN. Blesk i nishcheta antiretrovirusnoy terapii VICh-infektsii [Glitter and poverty of antiretroviral therapy for HIV infection]. Zh. klin. ta eksperym. med. doslidzhen'. 2013;1(4):372-84. (in Russian).
Al'tfel'd M, Berens G, Braun P. Khoffman K, Rokshtro YuK. Lechenie VICh-infektsii [Treatment of HIV infection]. Moskow: R.Valent; 2012. 736 p. (in Russian).
Obel N, Farkas DK, Kronborg G. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11:130-36.
Benson C, Ribaudo H, Zheng E. ACTG A5001/ALLRT Protocol Team. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal; 2009 (February 8-11 2009). 721 p.
Thompson MA, Aberg JA, Cahn P. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-33.
Lundgren J, Reiss P, Worm S. Aquataine, AHOD, ATHENA, INSIGHT, EuroSIDA, ICONA, Nice, SHCS, St Pierre cohorts, and D:A:D Study Group. Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: The D:A:D Study. Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal; 2009 (February 8-11 2009). 44LB p.
Seaberg EC, Munoz A, Lu M. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953-60.
Hsue P, Wu Y, Schnell A. Association of abacavir and HIV disease factors with endothelial function in patients on long-term suppressive ART. Ibid. 723 p.
Daar ES, Tierney T, Fischl MA. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann. Intern. Med. 2011;154:445-56.
Bedimo R, Westfall A, Drechsler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. Abstracts of the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa, 2009. MOAB202 p.
Behrens GM, Reiss P. Abacavir and cardiovascular risk. Curr. Opin. Infect. Dis. 2010;23:9-14.
Behrens G.M. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 2005;352:1721-22.
Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS. 2008;22:S19-S26.
Friis-Moller N, Weber R, Reiss P. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. IDS. 2003;17:1179-193.
Lang S, Mary-Krause M, Cotte L. Clinical Epi Group of the French Hospital Database on HIV. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal; 2009 (February 8-11 2009). 43LB p.
Crane Heidi M, Van Rompaey E, Kitahata M. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006;20:1019-026.
Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:3172.
Dube MP, Lipshultz SE, Fichtenbaum CJ. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation. 2008;118:36-40.
Rathbun CR, Liedtke MD, Blevins SM. Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir. HIV Clin. Trials. 2009;10:328-36.
Chow DC, Souza SA, Chen R. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin. Trials. 2003;4:411-16.
Currier JS, Lundgren DJ, Carr A. Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy. Circulation. 2008;118:29-35.
Frank J, Palella Jr, Phair JP. Cardiovascular Disease in HIV Infection. Curr. Opin. HIV AIDS. 2011;6:266-71.
Rogers JS, Zakaria S, Thom KA. Immune reconstitution inflammatory syndrome and human immunodeficiency virus-associated myocarditis. Mayo. Clin. Proc. 2008;83:1275-279.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 2007;92:2506-512.
Palella FJJr, Gange SJ, Benning L. Inflammatory biomarkers and abacavir use in the Women’s Interagency HIV Study and the Multicenter AIDS Cohort Study. Benning. AIDS. 2010;24:1657-665.
James HStein. Managing Cardiovascular Risk in Patients With HIV Infection. J. Acquir. Immune Defic. Syndr. 2005;38:115-23.
Jason VBaker, Jens Dlundgren. Cardiovascular implications from untreated human immunodeficiency virus infection. European Heart Journal. 2011;32:945-51.
Lars Ghemkens, Heiner Cbucher. HIV infection and cardiovascular disease. European Heart Journal. 2014;35:1373-381.
Mahmoud USani, Basil NOkeahialam. QTc Interval Prolongation in Patients with HIV and AIDS. Journal Of The National Medical Association. 2005;97:1657-661.
Emery S, Neuhaus JA, Phillips AN. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J. Infect. Dis. 2008;197:1133-144.
Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. Acquir. Immune. Defic. Syndr. 2007;44:493-99.
Ding XA, Cooper C, Miele P. No association of myocardial infarction with ABC use: An FDA Meta-analysis. Аbstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston; 2009. 808 p.
Dube MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin. Infect. Dis. 2008;47:567-74.
Molina JM, Villanueva JA, Echevarria J. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J. Acquir. Immune Defic. Syndr. 2010;53:323-32.
Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita. 2011;47:44-8.
Reinsch N, Buhr C, Krings P. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin. Trials. 2009;10:261-68.
Priscilla YH, Steven GD, Peter WH. Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults. The Journal of Infectious Diseases. 2012;205:375-82.
Charbit B, Rosier A, Bollens D. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a crosssectional study. Br. J. Clin. Pharmacol. 2009;67:76-82.
Kamin D, Hadigan C, Lehrke M. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J. Clin. Endocrinol. Metab. 2005;90:3423-426.
Saves M, Chene G, Ducimetiere P. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin. Infect. Dis. 2003;37:292-98.
El-Sadr WM, Grund B, Neuhaus J. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann. Intern. Med. 2008;149:289-99.
Bavinger C, Bendavid E, Niehaus K. Risk of cardiovascular disease from antiretroviral therapy for HIV: A Systematic Review. PLoS ONE. 2013;8:e59551.
Mangili A, Gerrior J, Tang AM. Risk of Cardiovascular Disease in a Cohort of HIVInfected Adults: A Study Using Carotid Intima-Media Thickness and Coronary Artery Calcium Score. Clinical Infectious Diseases. 2006;43:1482-489.
Worm SW, Sabin C, Weber R. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 2010;201:318-30.
Samuel AB. HIV and Cardiovascular Disease. Clinical Infectious Diseases. 2011;53:92-3.
McComsey G, Smith K, Patel P. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/ lamivudine or tenofovir/emtricitabine: The HEAT Study. Аbstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal; 2009 (February 8-11 2009). 683LС p.
Cooper D, Bloch M, Humphries A. STEAL Study Investigators. Simplification with fixeddose tenofovir/emtricitabine or abacavir/lamivudine in adults with suppressed HIV replication: The STEAL Study, a randomized, open-label, 96-week, non-inferiority trial. Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal; 2009 (February 8-11 2009). 576 p.
Chaubey SK, Sinha AK, Phillips E. Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection. Sex Health. 2009;6:254-57.
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2017 Kh. I. Vozna
Ця робота ліцензованаІз Зазначенням Авторства 3.0 Міжнародна.
Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
